Articles Archive for Year 2019
Press Releases»

New York, NY (Press Release) – Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced the completion of a proof of concept study of multiple myeloma with lenalidomide using a model which emulates transdermal delivery. The results of the study demonstrate that a continuous subcutaneous (SC) delivery of lenalidomide is superior in terms of efficacy and equivalent in tolerability when compared to a standard once daily pulsatile dosing of Revlimid® (Celgene Corporation) in mice. The positive outcome provides a clear path …
Press Releases»

Zurich-Schlieren, Switzerland (Press Release) – Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan Drug Designation by the US Food and Drug Administration (FDA) for its novel therapeutic, MP0250, for the treatment of multiple myeloma.
MP0250 is a first-in-class, tri-specific multi-DARPin® drug candidate neutralizing VEGF-A and HGF and is binding to human serum albumin to increase plasma half-life. The unique mechanism of action of MP0250 represents a new approach to targeting the tumor microenvironment and increase patients' …
Holiday»

As the 2019 holiday season reaches it peak, all of us here at The Myeloma Beacon would like to thank you, our readers and members of the myeloma community worldwide, for giving us the greatest gift possible: your time.
We appreciate your coming to The Beacon and reading our articles, letting us know your thoughts about them, and sharing your experiences and helping one another.
The holiday season is a time of many different traditions. It also is a busy time, when it is easy to lose track of …
Opinion»

Though it has been almost five years since my initial diagnosis, I still am somewhat uncertain about what it means to live with multiple myeloma. Where does enjoying your life, LIVING your life (having fun, laughing, enjoyment, etc.) fit in with the very real and serious circumstance of multiple myeloma?
When first diagnosed, I was sad, disappointed, uncertain, and scared. It was easy to be this way because I associated having multiple myeloma with constant and extreme pain, lots of suffering, so much sadness, and of course my coming death. I …
Press Releases»

Toronto, ON (Press Release) – Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”), is pleased to announce that it has signed a collaboration agreement with Mayo Clinic in Minnesota to conduct clinical studies to evaluate and validate the utility of the Company’s proprietary telomere analytics as a prognostic solution for Multiple Myeloma.
The collaboration studies will be led by Dr. Shaji Kumar, MD, and were designed to include two retrospective phases with the potential of a third prospective phase. For each phase, TELO’s analytics will be employed to: 1) predict …
Press Releases»

- IND clearance enables commencement of clinical trial to evaluate NEXI-002 in multiple myeloma patients who have failed >3 previous lines of therapy
- FDA action represents the Company’s second IND clearance in 4Q2019 for its pipeline of novel cellular therapy products
{{image}}Gaithersburg, MD (Press Release) – NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, has received IND clearance for the Company’s second cellular therapy product. NEXI-002 is being developed for the treatment of multiple myeloma patients that have failed at least three prior lines of therapy.
Scott P. Carmer, NexImmune’s President and CEO, commented, “FDA clearance of our second IND this quarter marks another significant milestone for NexImmune and demonstrates our team’s focus and …
Press Releases»

- Overall response rate (ORR) of 31% with 2.5 mg/kg regimen and no new safety signals in heavily pre-treated patient population who were refractory to an immunomodulatory drug and a proteasome inhibitor, and were refractory or intolerant to an anti-CD38 antibody
- Data published in The Lancet Oncology highlight the potential of belantamab mafodotin for patients with multiple myeloma whose disease has progressed
- GSK confirms submission of a Biologics License Application to the US Food and Drug Administration
{{image}}London, United Kingdom (Press Release) – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced treatment with the investigational single-agent belantamab mafodotin resulted in a clinically meaningful 31% overall response rate (ORR) with the 2.5 mg/kg regimen in patients with heavily pre-treated multiple myeloma. Patients in the trial received a median of seven prior lines of treatment, were refractory to an immunomodulatory drug and a proteasome inhibitor and were refractory and/or intolerant to an anti-CD38 antibody. The median duration of response has not been reached …